Status:

COMPLETED

SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling

Lead Sponsor:

Direction Centrale du Service de Santé des Armées

Conditions:

SARS-CoV 2

Eligibility:

All Genders

18+ years

Brief Summary

Since March 2020, SARS-CoV2 virus (nCoV19; COVID-19) is considered pandemic. Its high rate of spread and infection in the human population and the lack of effective and validated treatment have led th...

Eligibility Criteria

Inclusion

  • 18 years of age;
  • screened for SARS-CoV2 by RT-PCR from a nasopharyngeal swab within 96 hours prior to inclusion.

Exclusion

  • Patient admitted to intensive care;
  • Pregnant woman.

Key Trial Info

Start Date :

July 23 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 13 2021

Estimated Enrollment :

779 Patients enrolled

Trial Details

Trial ID

NCT04460638

Start Date

July 23 2020

End Date

August 13 2021

Last Update

September 6 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpital d'Instruction des Armées Laveran

Marseille, France, 13013

SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling | DecenTrialz